Literature DB >> 27207553

A Novel Function of Hepatic FOG2 in Insulin Sensitivity and Lipid Metabolism Through PPARα.

Yajie Guo1, Junjie Yu1, Jiali Deng1, Bin Liu1, Yuzhong Xiao1, Kai Li1, Fei Xiao1, Feixiang Yuan1, Yong Liu1, Shanghai Chen1, Feifan Guo2.   

Abstract

Friend of GATA 2 (FOG2) is a transcriptional cofactor involved mostly in cardiac function. The aim of this study was to investigate the role of hepatic FOG2 in insulin sensitivity and lipid accumulation. FOG2 overexpression by adenovirus-expressing FOG2 (Ad-FOG2) significantly attenuates insulin signaling in hepatocytes in vitro. Opposite effects were observed when FOG2 was knocked down through adenovirus-expressing small hairpin RNA for FOG2 (Ad-shFOG2). Furthermore, FOG2 knockdown by Ad-shFOG2 ameliorated insulin resistance in leptin receptor-mutated (db/db) mice, and FOG2 overexpression by Ad-FOG2 attenuated insulin sensitivity in C57BL/6J wild-type (WT) mice. In addition, Ad-FOG2 reduced, whereas Ad-shFOG2 promoted, hepatic triglyceride (TG) accumulation in WT mice under fed or fasted conditions, which was associated with increased or decreased hepatic peroxisome proliferator-activated receptor α (PPARα) expression, respectively. Moreover, the improved insulin sensitivity and increased hepatic TG accumulation by Ad-shFOG2 were largely reversed by adenovirus-expressing PPARα (Ad-PPARα) in WT mice. Finally, we generated FOG2 liver-specific knockout mice and found that they exhibit enhanced insulin sensitivity and elevated hepatic TG accumulation, which were also reversed by Ad-PPARα. Taken together, the results demonstrate a novel function of hepatic FOG2 in insulin sensitivity and lipid metabolism through PPARα.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27207553     DOI: 10.2337/db15-1565

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  2 in total

1.  ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimer's Disease Through Inflammation and Metabolism.

Authors:  Shougang Liu; Xiuqing Yuan; Hang Su; Fanghua Liu; Zhe Zhuang; Yongfeng Chen
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

2.  Hepatic metabolite responses to 4-day complete fasting and subsequent refeeding in rats.

Authors:  Xiukun Sui; Hailong Wang; Feng Wu; Chao Yang; Hongyu Zhang; Zihan Xu; Yaxiu Guo; ZhiFeng Guo; Bingmu Xin; Ting Ma; Yinghui Li; Zhongquan Dai
Journal:  PeerJ       Date:  2022-09-20       Impact factor: 3.061

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.